A case of disseminated erythematous drug eruption caused by favipiravir in a patient with COVID ‐19

Favipiravir is an RNA-dependent RNA polymerase inhibitor that was developed as a therapeutic agent for novel or reemerging influenza infections. Favipiravir rarely causes skin disorders, and seven cases of drug eruption have previously been reported as follows: three with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. 5–7 To the best of our knowledge, this is the first report of positive patch tests leading to a definitive diagnosis. Since multiple drugs are used for COVID-19 patients, the possibility of drug eruption must be considered when diagnosing a rash. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.